Use of CGM has been associated with decreased risk for acute diabetes events (ADE) in patients treated with insulin therapy. In this study, we investigated the relationship of continuous glucose monitoring (CGM) use and ADE, all-cause hospitalizations (ACH), and emergency department (ED) visits among people with type 2 diabetes (T2D), treated with sulfonylurea (SU) or meglitinide therapy in the United States. This retrospective cohort study searched Inovalon Insights claims data for individuals with T2D, treated with SU/meglitinide, excluding insulin or GLP-1 RA users, and using FreeStyle Libre (FSL) between 01/2017 and 09/2023. Subgroup analysis was performed among participants <65 and ≥65 years old. Two subgroups were analyzed: <65 group: N = 2,976, mean age 54 ± 9 years, 41% female; ≥65 group: N = 1,895, mean age 73 ± 6 years, 43% female. For both subgroups, ADE, acute hyperglycemic events, ACH, and ED visit rates were significantly lower during CGM use period, compared to pre-CGM use (Table 1). Compared to pre-CGM use, patients on CGM with type 2 diabetes treated with SU/meglitinides had lower healthcare utilization. Further research should assess the financial and patient impact of these event reductions.
R.J. Galindo: Consultant; Abbott. Other Relationship; Dexcom, Inc. Consultant; Bayer Inc. Other Relationship; Novo Nordisk, Eli Lilly and Company. Consultant; Boehringer-Ingelheim, AstraZeneca. B. Burugapalli: Other Relationship; Riya Soft Solutions Inc. L. Brandner: Employee; Abbott. A. Bindal: Employee; Abbott.
